Trials / Completed
CompletedNCT02440620
Cardiac Toxicity in Medical Treatment of Breast Cancer
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 45 (actual)
- Sponsor
- Odense University Hospital · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study will describe the epidemiology including prognosis of heart failure related to treatment with anthracycline and trastuzumab for breast cancer. In a prospective study Human Epidermal Growth Factor Receptor 2 (HER2) positive breast cancer patients scheduled for trastuzumab treatment at Odense University Hospital, will be offered advanced echocardiographic examination, test of bio-markers and genetic markers for the purpose of investigating if early identification of patients in particular risk of developing heart failure is feasible.
Conditions
Timeline
- Start date
- 2014-10-01
- Primary completion
- 2018-08-01
- Completion
- 2018-08-01
- First posted
- 2015-05-12
- Last updated
- 2019-05-01
Locations
1 site across 1 country: Denmark
Source: ClinicalTrials.gov record NCT02440620. Inclusion in this directory is not an endorsement.